Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Xiangjie Fu, Tan Tan & Peijun Liu. (2020) Regulation of Autophagy by Non-Steroidal Anti-Inflammatory Drugs in Cancer. Cancer Management and Research 12, pages 4595-4604.
Read now
Read now
Articles from other publishers (21)
Eric A. Goethe, Amy B. Heimberger & Ganesh Rao. (2023) Aspirin and immunotherapy: a Faustian bargain?. Journal of Clinical Investigation 133:9.
Crossref
Crossref
Junyu Wu, Yau‐Tuen Chan, Yuanjun Lu, Ning Wang & Yibin Feng. (2023) The tumor microenvironment in the postsurgical liver: Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma. Medicinal Research Reviews.
Crossref
Crossref
. (2023) 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Journal of Liver Cancer 23:1, pages 1-120.
Crossref
Crossref
Runzhi Zhao, Xiyuan Xu, Li Sun & Guohua Zhang. (2023) Long-term effect of anesthesia choice on patients with hepatocellular carcinoma undergoing open liver resection. Frontiers in Oncology 12.
Crossref
Crossref
Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Guang-Xiao Meng, Kai-Xuan Liu, Zi-Niu Ding, Jian-Guo Hong, Zhi-Qiang Chen, Zhao-Ru Dong & Tao Li. (2022) Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis. Journal of Clinical and Translational Hepatology 10:5, pages 835-846.
Crossref
Crossref
. (2022) 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology 28:4, pages 583-705.
Crossref
Crossref
Nidheesh Thadathil, Ramasamy Selvarani, Sabira Mohammed, Evan H. Nicklas, Albert L. Tran, Maria Kamal, Wenyi Luo, Jacob L. Brown, Marcus M. Lawrence, Agnieszka K. Borowik, Benjamin F. Miller, Holly Van Remmen, Arlan Richardson & Sathyaseelan S. Deepa. (2022) Senolytic treatment reduces cell senescence and necroptosis in Sod1 knockout mice that is associated with reduced inflammation and hepatocellular carcinoma. Aging Cell 21:8.
Crossref
Crossref
Luca G. Guidotti, Carlo La Vecchia & Massimo Colombo. (2022) Low‐dose aspirin reduces the risk of HBV‐associated HCC even when administered short‐term: Too good to be true?. Hepatology 76:2, pages 300-302.
Crossref
Crossref
Jin Lin Tan, Sandeep Sidhu-Brar, Richard Woodman & Mohamed Asif Chinnaratha. (2022) Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer.
Crossref
Crossref
Mengshi Yi, Xi Feng, Wei Peng, Fei Teng, Youyin Tang & Zheyu Chen. (2022) Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease. European Journal of Clinical Pharmacology 78:4, pages 647-656.
Crossref
Crossref
Xueliang Zhou, Tengfei Zhang, Yali Sun, Chunwei Li, Xianfei Ding, Yanhui Zhu, Lifeng Li & Zhirui Fan. (2022) Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma. Frontiers in Pharmacology 13.
Crossref
Crossref
. (2022) 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology 23:12, pages 1126.
Crossref
Crossref
Yuwei Liu, Tianqi Ren, Xiaotong Xu & Jinglan Jin. (2021) Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies. European Journal of Cancer Prevention 31:1, pages 35-43.
Crossref
Crossref
Xiaofei Li, Yuexiao Yu & Liwen Liu. (2021) Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis. Clinics and Research in Hepatology and Gastroenterology 45:6, pages 101545.
Crossref
Crossref
Regina Zi Hwei Tan, Ian Lockart, Christina Abdel Shaheed & Mark Danta. (2021) Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 54:4, pages 356-367.
Crossref
Crossref
Emanuela Ricciotti, Kirk J. Wangensteen & Garret A. FitzGerald. (2021) Aspirin in Hepatocellular Carcinoma. Cancer Research 81:14, pages 3751-3761.
Crossref
Crossref
Yen-Hsiang Liao, Ren-Jun Hsu, Tzu-Hwei Wang, Chen-Ta Wu, Sheng-Yao Huang, Chung-Y. Hsu, Yuan-Chih Su, Wen-Lin Hsu & Dai-Wei Liu. (2020) Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. BMC Gastroenterology 20:1.
Crossref
Crossref
Yongxi Song, Xi Zhong, Peng Gao, Cen Zhou, Jinxin Shi, Zhonghua Wu, Zhexu Guo & Zhenning Wang. (2020) Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review. Frontiers in Endocrinology 11.
Crossref
Crossref
Jia-yin Hou, Hua-yu Wu, Rong-quan He, Peng Lin, Yi-wu Dang & Gang Chen. (2019) Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases. Pathology - Research and Practice 215:1, pages 177-194.
Crossref
Crossref
Chin-Hsiao Tseng. (2018) Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver International 38:11, pages 2018-2027.
Crossref
Crossref
C.-L. Lin & J.-H. Kao. (2018) Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 48:1, pages 5-14.
Crossref
Crossref